Search for dissertations about: "Drug Costs"

Showing result 1 - 5 of 112 swedish dissertations containing the words Drug Costs.

2. 1. Quality, costs and the role of primary health care

   Author : Sven Engström; Lars Borgquist; Ingvar Krakau; Linköpings universitet; []
   Keywords : Drug utilization review methods; Hospitalization statistics and numerical data; Outpatient clinics; hospital utilization; Primary health care; Quality of health care; Respiratory tract infections; drug therapy; Family practice; Cost-benefit analysis; Efficiency; Organizational; Health care costs; MEDICINE; MEDICIN;

   Abstract : The general aim of this thesis is to describe and analyse the role of primary care in health care systems in terms of health, health care utilisation and costs, and to study the feasibility of retrieval of data from computerised medical records to monitor medical quality.The thesis includes five studies, a systematic literature review, a register study of utilisation of hospital and primary care, a study based on data from computerised medical records of individual patients cost for primary care, and two studies of management of respiratory infections in primary care based on data from computerised medical records of twelve health centres. READ MORE

4. 2. Clinical and Experimental Studies in Peritoneal Metastases from Gastric Cancer

   Author : Bo Hultman; Haile Mahteme; Bruno Walther; Uppsala universitet; []
   Keywords : MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; gastric cancer; peritoneal metastases; peritoneal carcinomatosis; epidemiology; prognostic factor; survival; neoadjuvant chemotherapy; cytoreductive surgery; HIPEC; health economy; costs; systemic chemotherapy; cultured tumor cells; fluorometric analysis; cancer drug tests; chemo-sensitivity; anti tumor drugs.; Surgery; Kirurgi;

   Abstract : Gastric cancer (GC) is one of leading causes of death in the world, and peritoneal metastases (PM) are a major site of recurrence. PM from GC implies a poor prognosis, with median overall survival (mOS) approximately 3 months and no survival at five years. READ MORE

5. 3. Towards Individualized Drug Dosage - General Methods and Case Studies

   Author : Martin Fransson; Peter Fritzson; Lena Friberg; Linköpings universitet; []
   Keywords : NATURAL SCIENCES; NATURVETENSKAP; NATURVETENSKAP; NATURAL SCIENCES; drug dosage; population pharmacokinetics; biochemical modelling; identifiability; parameter estimation; Bioinformatics; Bioinformatik;

   Abstract : Progress in individualized drug treatment is of increasing importance, promising to avoid much human suffering and reducing medical treatment costs for society. The strategy is to maximize the therapeutic effects and minimize the negative side effects of a drug on individual or group basis. READ MORE

6. 4. Generic Drug Switch in Epilepsy – Pharmacokinetic and Clinical Aspects

   Author : Patrik Olsson; Helsingborg Kliniska Vetenskaper; []
   Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Generic drug; Antiepileptic drugs; Pharmacokinetics; Treatment outcome;

   Abstract : Background and aim: Generic drugs contain the same active ingredients as brand- name drugs, with the advantage of much lower costs. The aim of this thesis was to contribute new knowledge to the ongoing debate on the safety of generic antiseizure drug (ASD) substitutions. There was a particular emphasis on the pharmacokinetic and clinical outcomes. READ MORE

7. 5. On drug use, multiple medication and polypharmacy in a national population

   Author : Bo Hovstadius; Göran Petersson; Sven Tågerud; Bengt Åstrand; Björn Wettermark; Linnéuniversitetet; []
   Keywords : drug use; multiple medication; polypharmacy; register; prevalence; therapeutic intensity; acquisition cost.; NATURAL SCIENCES; NATURVETENSKAP; Biomedical Sciences; Biomedicinsk vetenskap;

   Abstract : The application of multiple medications has successively increased during a number of years and has thereby increased the potential risks of adverse drug reactions, interactions and non-adherence to drug therapy. This may result in unnecessary health expenditure, directly due to redundant drug sales, and indirectly due to the increased hospitalization caused by drug-related problems. READ MORE